Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2008-09-30
2008-09-30
Minnifield, N. M. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S234100, C424S247100, C530S300000, C530S324000
Reexamination Certificate
active
10934812
ABSTRACT:
Methods for treating stretch marks by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a stretch mark.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6261572 (2001-07-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6623742 (2003-09-01), Voet
patent: 6667041 (2003-12-01), Schmidt
patent: 6787517 (2004-09-01), Gil et al.
patent: 2002/0081291 (2002-06-01), Hawrot
patent: 2003/0224019 (2003-12-01), O'Brien
patent: 2004/0009180 (2004-01-01), Donovan
patent: 198 52 981 (1998-11-01), None
patent: WO 96/33273 (1996-04-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 00/10598 (2000-03-01), None
patent: WO 00/15245 (2000-03-01), None
patent: WO 00/57897 (2000-03-01), None
patent: WO 00/74703 (2000-05-01), None
patent: WO 01/21213 (2001-03-01), None
patent: WO 01/70132 (2001-09-01), None
patent: WO 01/70291 (2001-09-01), None
patent: WO 03/011333 (2003-02-01), None
Zheng et al (Br. Dermatol. Feb. 1985; 112(2):185-93)(Abstract only).
Webster's II New Riverside University Dictionary, THe Riverside Publishing Company, 1984.
Hyde (TeensHealth, Nemours Foundation, date reviewed Apr. 2004).
Brandt et al (Dermatol Clin 22 (2004) 159-166).
Freund et al (The Journal of Pain, vol. 4, Issue 3, Apr. 2003, pp. 159-165)(Abstract only).
Keen et al (Plastic and Reconstructive Surgery, Jul. 1994, 94, No. 1, pp. 94-99).
Aoki, K., et al,Mechanisms of the antinociceptive effect of subcutaneous Botox: Inhibition of peripheral and central nociceptive processing, Cephalalgia Sep. 2003;23(7):649.
Andreadis, S., et al.,Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system, FASEB J. Apr. 2001;15(6):898-906.
Arredondo, J., et al.,Central role of alpha7 nicotinic receptor in differentiation of the stratified squamous epithelium, J Cell Biol. Oct. 28, 2002;159(2):325-36.
Asahina A., et al.,Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects, Proc Natl Acad Sci U S A. Aug. 29, 2005;92(18):8323-7.
Bigalke, H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-324:1985.
Bigalke, H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz, T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990.
Blugerman, G., et al.,Multiple eccrine hidrocystomas: A new therapeutic option with botulinum toxin, Dermatol Surg May 2003;29(5):557-9.
Borodic et al.,Pharmacology and Histology fo the therapeutic Application of Botulinum Toxin, Therapy With Botulinum Toxin, Ed. Jankovic, J., et al., Marcel Dekker, Inc., (1994) p. 150.
Brem, H., et al,Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent Gliomas, Lancet 345;1008-1012:1995.
Bushara, K.,Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3):507.
Chen, W., et al.,Trophic interactions between sensory nerves and their targets, Journal of Biomedical Science. 1999;6(2):79-85.
Chiang, H-Y, et al.,Regional difference in epidermal thinning after skin denervation, Exp Neurol 1998;154(1):137-45.
Chien, Hsiung-F., et al., (2001)Quantitative pathology of cutaneous nerve terminal degeneration in the human skin, Acta Neuropathologica 102:455-461.
Childers et al., (2002), American Journal of Physical Medicine & Rehabilitation, 81:751-759.
Coffield et al.,Site and Action of Botulinum Neurotoxin, Therapy With Botulinum Toxin, Ed. Jankovic, J., et al., Marcel Dekker, Inc., (1994), p. 5.
Dabrowski, E., et al.,Botulinum toxin as a novel treatment for self mutilation in Lesch-Nyhan syndrome, Ann Neurol Sep. 2002;52(3 Supp 1):S157.
Doggweiler, R., et al.,Botulinum toxin type A causes diffuse and highly selective atrophy of rat prostate, Neurourol Urodyn 1998;17(4):363.
Fung, L. K. et al.,Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain, Cancer Research 58; 672-684:1998.
Goldman, (2000), Aesthetic Plastic Surgery Jul.-Aug. 24(4):280-282.
Gonelle-Gispert, Carmen, et al.,SNAP-25a and -25b Isoforms are Both Expressed in Insulin-Secreting Cells and Can Function in Insulin Secretion, Biochem J. (1999) 339 (pt 1); pp. 159-165.
Grando, S. et al.,Human keratinocytes synthesize, secrete and degrade acetylcholine, J Invest Dermatol. Jul. 1993;101(1):32-6.
Grando, S.,Biological functions of keratinocyte cholinergic receptors, J Investig Dermatol Symp Proc. Aug. 1997;2(1):41-8.
Grando, S., et al.,Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. Invest Dermatol. Sep. 1996;107(3):412-8.
Grando, S., et al.,Keratinocyte muscarinic acetylcholine receptors: immunolocalization and partial characterization, J Invest Dermatol. Jan. 1995;104(1):95-100.
Griffin, J., et al.,Axonal degeneration and disorders of the axonal cytoskeleton. In: Waxman S., et al.,The Axon. New York: Oxford University Press, 1995:375-390.
Habermann, E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988.
Habermann, E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Habermann, E.,Naunyn-Schmiedeberg's Arch. Pharmacol. 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill.
Heckmann, M., et al.,Botulinum toxin type A injection in the treatment of lichen simplex: An open pilot study, J Am Acad Dermatol Apr. 2002;46(4):617-9.
Hokfelt, T.,Neuropeptides in perspective : The last ten years, Neuron 1991; 7: 867-879.
Hosoi, J., et al.,Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide, Nature. May 13, 1993;363(6425):159-63.
Hsieh, S., et al.,Epidermal denervation and its effects on keratinocytes and Langerhans cells, J Neurocytol 1996;25:513-524.
Hsieh, S., et al.,Modulation of keratinocyte proliferation by skin innervation. Journal of Investigative Dermatology, 1999;113(4):579-86.
Hsieh, S., et al.,Pathology of nerve terminal degeneration in the skin, Journal of Neuropathology & Experimental Neurology. 2000;59(4):297-307.
Hsieh, S., et al.,Skin innervation and its influence on the epidermis, J Biomed Sci 1997;4:264-268.
Huang, et al.,Influence of cutaneous nerves on keratinocyte proliferation and epidermal thickness in mice, Neuroscience. 1999;94(3):965-73.
Inaba, N., et al.,Capsaicin-induced calcitonin gene-related peptide release from isolated rat stomach measured with a new chemiluminescent enzyme immunoassay, Jpn J Pharmacol. Nov. 1996;72(3):223-9.
Johnson, M.,Synaptic glutamute release by postnatal rat serotonergic neurons in microculture, Neuron 1994; 12: 433-442.
Jost, W.,Ten years' experience with botulinum toxin in anal fissure, Int J Colorectal Dis Sep. 20
Allergan Inc.
Donovan Stephen
Ford Vanessa L.
Minnifield N. M.
Nassif Claude L.
LandOfFree
Stretch mark treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stretch mark treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stretch mark treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3911289